A study to learn BAY 3498264 when given alone or together with sotorasib in participants who have advanced solid cancers with specific genetic changes called KRASG12C mutation
22676
Phase 1 other active
Quick answer
A study to learn BAY 3498264 when given alone or together with sotorasib in participants who have advanced solid cancers with specific genetic changes called KRASG12C mutation for Advanced solid tumors harboring KRAS G12C mutation is a Phase 1 program (other) at Bayer AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer AG
- Indication
- Advanced solid tumors harboring KRAS G12C mutation
- Phase
- Phase 1
- Modality
- other
- Status
- active